Promoter hypomethylation and upregulation of trefoil factors in prostate cancer

International Journal of Cancer

Volumn 127, Issue 8, 2010, Pages 1857-1865

  Vestergaard, Else Marie ^a   Nexø, Ebba ^a   Tørring, Niels ^a   Borre, Michael ^a   Ørntoft, Torben Falck ^a   Sørensen, Karina Dalsgaard ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

epigenetics; methylation; prostate cancer; trefoil factors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; TRANSCRIPTION FACTOR; TREFOIL PEPTIDE; PEPTIDE; TFF1 PROTEIN, HUMAN; TFF3 PROTEIN, HUMAN; TREFOIL FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER STAGING; CELL LINE; CLINICAL ARTICLE; CPG ISLAND; DEMETHYLATION; ENHANCER REGION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; REGULATORY MECHANISM; START CODON; UPREGULATION; ADENOCARCINOMA; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR CELL CULTURE;

ADENOCARCINOMA; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PEPTIDES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 77956998042     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25209     Document Type: Article

References (52)

1. Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM,. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007; 12: 4254-66.
2. Dobosy JR, Roberts JL, Fu VX, Jarrard DF,. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007; 177: 822-31.
3. Jones PA,. DNA methylation and cancer. Oncogene 2002; 21: 5358-60.
4. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM,. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7: 523-35.
5. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68: 8954-67.
6. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR,. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007; 26: 6560-5.
7. Thim L,. Trefoil peptides: from structure to function. Cell Mol Life Sci 1997; 53: 888-903.
8. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE,. Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 2004; 61: 209-14.
9. Colombel M, Dante R, Bouvier R, Ribieras S, Pangaud C, Marechal JM, Lasne Y,. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. J Urol 1999; 162: 927-30.
10. Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, Bruyneel E, Gespach C,. Trefoil factor family (TFF) peptides and cancer progression. Peptides 2004; 25: 885-98.
11. Taupin D, Ooi K, Yeomans N, Giraud A,. Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest 1996; 75: 25-32.
12. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR,. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002; 160: 1745-54.
13. Emami S, Le Floch NN, Bruyneel E, Thim L, May F, Westley B, Rio MC, Mareel M, Gespach C,. Induction of scattering and cellular invasion by trefoil peptides in src-and RhoA-transformed kidney and colonic epithelial cells. FASEB J 2001; 15: 351-61.
14. Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S,. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase-and thromboxane A2 receptor-dependent signaling pathways. FASEB J 2001; 15: 1517-28.
15. Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, Westley BR, May FE, Thim L, Mareel M, Gespach C, Emami S,. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003; 17: 7-16.
16. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Jr., Hampton GM,. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 5974-8.
17. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM,. Delineation of prognostic biomarkers in prostate cancer. Nature 2001 23; 412: 822-6.
18. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB,. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001; 61: 4683-8.
19. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM,. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004; 61: 215-27.
20. Bonkhoff H, Stein U, Welter C, Remberger K,. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995; 26: 824-8.
21. Vestergaard EM, Borre M, Poulsen SS, Nexo E, Tørring N,. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 2006; 12: 807-12.
22. Tomasetto C, Rockel N, Mattei MG, Fujita R, Rio MC,. The gene encoding the human spasmolytic protein (SML1/hSP) is in 21q 22.3, physically linked to the homologous breast cancer marker gene BCEI/pS2. Genomics 1992; 13: 1328-30.
23. Chinery R, Williamson J, Poulsom R,. The gene encoding human intestinal trefoil factor (TFF3) is located on chromosome 21q22.3 clustered with other members of the trefoil peptide family. Genomics 1996; 32: 281-4.
24. Gott P, Beck S, Machado JC, Carneiro F, Schmitt H, Blin N,. Human trefoil peptides: genomic structure in 21q22.3 and coordinated expression. Eur J Hum Genet 1996; 4: 308-15.
25. Beck S, Sommer P, Blin N, Gott P,. 5?-flanking motifs control cell-specific expression of trefoil factor genes (TFF). Int J Mol Med 1998; 2: 353-61.
26. Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le DA, Dutrillaux B, Calvo F,. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer 1995; 62: 724-31.
27. Sørensen KD, Borre M, ørntoft TF, Dyrskjøt L, Tørring N,. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer. Int J Cancer 2008; 122: 509-19.
28. Vestergaard EM, Poulsen SS, Grønbaek H, Larsen R, Nielsen AM, Ejskjaer K, Clausen JT, Thim L, Nexo E,. Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002; 48: 1689-95.
29. Vestergaard EM, Brynskov J, Ejskjaer K, Clausen JT, Thim L, Nexo E, Poulsen SS,. Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 2004; 64: 146-56.
30. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T,. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933-42.
31. Habbema JDF, Eijkemans R, Krijnen P, Knottnerus JA,. Analysis of data on the accuracy of diagnostic tests. In:, Knottnerus JA, editor. The evidence base of clinical diagnosis. London, BMJ Publishing Group; 2002. pp. 117-144.
32. Casadei R, Strippoli P, D'Addabbo P, Canaider S, Lenzi L, Vitale L, Giannone S, Frabetti F, Facchin F, Carinci P, Zannotti M,. mRNA 5? region sequence incompleteness: a potential source of systematic errors in translation initiation codon assignment in human mRNAs. Gene 2003; 321: 185-93.
33. Martin V, Ribieras S, Song-Wang X, Rio MC, Dante R,. Genomic sequencing indicates a correlation between DNA hypomethylation in the 5? region of the pS2 gene and its expression in human breast cancer cell lines. Gene 1995; 157: 261-4.
34. Fox KE, Colton LA, Erickson PF, Friedman JE, Cha HC, Keller P, MacDougald OA, Klemm DJ,. Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem 2008; 283: 35096-105.
35. Garcia GE, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP,. Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia 2006; 8: 523-33.
36. Reamon-Buettner SM, Borlak J,. Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. Cancer Res 2008; 68: 7587-96.
37. Tierney RJ, Kirby HE, Nagra JK, Desmond J, Bell AI, Rickinson AB,. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J Virol 2000; 74: 10468-79.
38. Prendergast GC, Ziff EB,. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 1991; 251: 186-9.
39. Bednarik DP, Duckett C, Kim SU, Perez VL, Griffis K, Guenthner PC, Folks TM,. DNA CpG methylation inhibits binding of NF-kappa B proteins to the HIV-1 long terminal repeat cognate DNA motifs. New Biol 1991; 3: 969-76.
40. Khoubehi B, Kessling AM, Adshead JM, Smith GL, Smith RD, Ogden CW,. Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J Urol 2001; 165 (6 Part 1): 2115-20.
41. Tyagi A, Agarwal R, Agarwal C,. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 2003; 22: 1302-16.
42. van BA, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57: 205-25.
43. Hsieh CL,. Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 1994; 14: 5487-94.
44. Martin V, Ribieras S, Song-Wang XG, Lasne Y, Frappart L, Rio MC, Dante R,. Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J Cell Biochem 1997; 65: 95-106.
45. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M,. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63: 4158-66.
46. Okada H, Kimura MT, Tan D, Fujiwara K, Igarashi J, Makuuchi M, Hui AM, Tsurumaru M, Nagase H,. Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int J Oncol 2005; 26: 369-77.
47. Carvalho R, Kayademir T, Soares P, Canedo P, Sousa S, Oliveira C, Leistenschneider P, Seruca R, Gott P, Blin N, Carneiro F, Machado JC,. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest 2002; 82: 1319-26.
48. Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, et al. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2009; 15: 1400-10.
49. Ehrlich M,. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400-13.
50. Gardiner-Garden M, Frommer M,. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261-82.
51. Ribieras S, Lefebvre O, Tomasetto C, Rio M,. Mouse Trefoil Factor genes: genomic organization, sequences and methylation analyses. Gene 2001; 266: 67-75.
52. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68: 8954-67.